Carnosine protects against doxorubicin-induced cardiotoxicity

Saudi Pharmaceutical Journal

Volumn 11, Issue 1-2, 2003, Pages 23-31

  Assiri, Adel M A ^a   Abdel Wahab, Ali F I ^a  

^a UMM AL QURA UNIVERSITY   (Saudi Arabia)

Author keywords

Antioxidants; Biomarkers; Cardioprotection; Cardiotoxicity; Carnosine; Doxorubicin

Indexed keywords

CARNOSINE; CREATINE KINASE; DOXORUBICIN; LACTATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTROCARDIOGRAM; HISTOPATHOLOGY; MALE; NONHUMAN; RAT; TREATMENT OUTCOME;

EID: 0038710736     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G and Szabo C. Activation of poly (ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther. 2002; 300 (3): 862-7.
2. Ogura M. Adriamycin (doxorubicin). Gan To Kagaku Ryoho. 2001; 28 (10): 1331-8 (Abstract).
3. Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med. 1991; 324: 843-5.
4. Nousiainen T, Vanninen E, Rantala A, Jantunen E and Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J Intern Med. 1999; 245: 359-64.
5. Steinherz LJ, Steinherz PG and Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: series of 15 patients. Med Pediatr Oncol. 1995; 24: 352-61.
6. Parussi D, Indolfi P, Casale F, Coppolino P, Tedesco MA and Tullio MT. Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chem. 2001; 8 (13): 1649-60.
7. Keizer H, Pinedo H, Schurhuis G and Joenje H. Doxorubicin (adriamycin): a critical review of free radical dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990; 47: 219-31.
8. Zhou S, Palmeira CM and Wallace KB. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett. 2001; 121 (3): 151-7.
9. Ciaccio M, Valenza M, Tesoriere L, Bongiomo A, Albiero R and Livrea MA. Vitamin A inhibits doxorubicin-induced membrane lipid peroxidation in rat tissues in- vivo. Arch Biochem Biophys. 1993; 302: 103-8.
10. Nowak D, Pierscinski G and Drzewoski J. Ambroxol inhibits doxorubicin-induced lipid peroxidation in mice. Free Rad Biol Med. 1995; 19: 659-63.
11. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol. 1998; 124: 425-7.
12. Xu M and Ashraf M, Melatonin protection against lethal myocyte injury induced by doxorubicin as reflected by effects on mitochondrial membrane potential. J Mol Cell Cardiol. 2002; 34 (1): 75-9.
13. Kohen R, Yamamoto Y, Cundy KC and Ames BN: Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc Natl Acad Sci USA. 1988; 85: 3175-9.
14. Hartman PE. Antimutagenesis and Anticarcinogenesis Mechanisms, eds; Shankel DM, Hartman PE, Kado T and Hollaender A, Plenum, New York, 1986: 169-79.
15. Fontana M, Pinnen F, Lucente G and Pecci L. Prevention of peroxynitrite-dependent darnage by carnosine and related sulphonamido pseudodipeptides. Cell Mol Life Sci. 2002; 59 (3): 546-51.
16. Kang JH, Kim KS, Choi SY, Kwon HY, Won MH and Kang TC. Protective effects of carnosine, homocarnosine and anserine against peroxyl radical-mediated Cu,Zn-superoxide dismutase modification. Biochim Biophys Acta. 2002; 1570 (2): 89-96.
17. Timioglu O, Kutsal S, Ozkur M, Uluoglu O, Aricioglu A, Cevik C, Duzgun E, Sancak B and Poyraz A. The effect of EGb 761 on the doxorubicin cardiomyopathy. Res Commun Mol Pathol Pharmacol. 1999; 106 (3): 181-92.
18. th ed. 1978; 12.
19. Panteghini M, Gerhardt W, Apple F, Ravkilde J and Wu AH. Quality specifications for cardiac troponin assays. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), Scientific Division- Committee on Standerdization of markers of Cardiac Damage. Clin Chem Lab Med. 2001; 141: 383-90.
20. Szasz G, Gruber W and Bernt E. Creatine kinase in serum: 1. Determination of optimum reaction conditions. Clin Chem. 1976; 22 (5): 650-6.
21. Recommendations of the German Society for Clinical Chemistry. Standardization of methods for the determination of enzyme activities in biological fluids. Z Klin Chem Klin Biochem. 1970; 8: 658-60.
22. Hellmann K. Preventing the cardiotoxicity of anthracyclines by dexrazoxane. BMJ. 1999; 319: 1086-6.
23. Suter TM and Meier B. Detection of anthracycline-induced cardiotoxicity: is there light at end of the tunnel. Ann Oncol. 2002; 13: 647-9.
24. Singal PK and Iliskovic N. Doxorubicin-induced Cardiomyopathy. N Engl J Med. 1998; 339 (13): 900-5.
25. Praga C, Beretta G, Vigo PL, Lenaz GR and Bonadonna G. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep. 1979; 63: 827-34.
26. Saad SY, Najjar TA and Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol Res. 2001; 43 (3): 211-8.
27. Herman EH. Use of cardiac troponin levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 1998; 58: 195-7.
28. Cardinale D, Sandri MT and Martinoni A. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002; 13: 710-5.
29. Dowd NP, Scully M, Adderley SR, Cunningham AJ and Fitzgerald DJ. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest. 2001; 108: 585-90.
30. Herman EH, Zhang J, Rifai N, Lipshultz SE, Hasinoff BB, Chadwick DP, Knapton A, Chai J and Ferrans VJ. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol. 2001; 48 (4): 297-304.
31. Mostafa AM, Nagi MN, Al Rikabi AC and El-Kashef HA. Protective effect of aminoguanidine against cardiovascular toxicity of chronic doxorubicine treatment in rats. Res Commun Mol Pathol Pharmacol. 1999; 106 (3): 193-202.
32. Singal PK, Iliskovic N, Li T and Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997; 11: 931-6.
33. Burke BE, Gambliel H, Olson RD, Bauer FK and Cusack BJ. Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycIine cardiomyopathy in the rat. Br J Pharmacol. 2000; 131: 1-4.
34. Swain SM, Whaley FS, Gerber MC and Weisberg S. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997; 15: 1318-32.
35. Acker FA, Boven E, Kramer K, Haenen GR and Vijgh WJ. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity. Clin Cancer Res. 2001; 7 (5): 1378-84.
36. Sacco G, Bigioni M, Evangelista S, Manzini S and Maggi CA. Cardioprotective effects of zofinopril, a new angiotensin-Conve-rting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001; 414 (1): 71-8.
37. Sharonov BP, Govorova NU and Lyziova SN. Carnosine as apotential scavenger of oxidants generated by stimulated neutrophils. Biochem Internat. 1990; 21 (1): 61-8.
38. Decker EA, Ivanov V, Zhu BZ and Frei B. Inhibition of low-density lipoprotein oxidation by carnosine histidine. J Agric Food Chem. 2001; 49 (1): 511-6.
39. Nagasawa T, Yonekura T, Nishizawa N and Kitts DD. In vitro and in vivo inhibition of muscle lipid and protein oxidation by carnosine. Mol Cell Biochem. 2001; 225 (1): 29-34.
40. Danesi R, Bernardini N, Agen C, Costa M, Macchiarini P, Dellatore P and DeItacca M. Cardiotoxicity and cytotoxicity of the anthracycline analog 4-deoxy-4-iodo-doxorubicin. Toxicology. 1991; 70: 243-53.
41. Zaloga GP, Roberts P, Black K, Lin M, Sudo RT and Nelson TE. Carnosine is a novel peptide modulator of intracellular calcium and contractility in cardiac cells. Am J Physiol. 1997; 272 (1 Pt 2): H462-8.
42. Gambliel HA, Burke BE, Cusack BJ, Walsh GM, Zhang YL, Mushlin PS and Olson RT. Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochem Biophys Res Commun. 2002; 291 (3): 433-8.
43. Bharadwaj LA, Davies GF, Xavier IJ and Ovsenek N. Carnosine and verapamil inhibit hypoxia-induced expression of hypoxia inducible factor (HIF-1 alpha) in H9c2 cardiomyoblasts. Pharmacol Res. 2002; 45 (3): 175-8